Evidence map›Paper›PMID 35799508›Full record

ReviewNeural regeneration research2023

Neurotrophic fragments as therapeutic alternatives to ameliorate brain aging.

Itzel Ortiz Flores, Samuel Treviño, Alfonso Díaz

Registry-linked trialAbstract readReview
In one paragraph

Review in Neural regeneration research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06677502 (The Usefulness of Cerebrolysin in Alleviating the Severity of Delirium in Critically Ill Patients), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06677502 naenrolling by invitationnot on this mapstarted 2024, after this paper: background citation

The Usefulness of Cerebrolysin in Alleviating the Severity of Delirium in Critically Ill Patients

TypeinterventionalSponsorMedical University of LublinRan2024 to 2025Enrolled500ConditionsCognitive ImpairmentArmsCerebrolysin, Saline Solution - IV
3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Itzel Ortiz FloresDepartment of Health Sciences, School of Medicine, University of the Americas Puebla, Puebla, Mexico.
Samuel TreviñoFaculty of Chemical Sciences, Benemerita Autonomous University of Puebla, Puebla, Mexico.
Alfonso DíazFaculty of Chemical Sciences, Benemerita Autonomous University of Puebla, Puebla, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aging is a global phenomenon and a complex biological process of all living beings that introduces various changes. During this physiological process, the brain is the most affected organ due to changes in its structural and chemical functions, such as changes in plasticity and decrease in the number, diameter, length, and branching of dendrites and dendritic spines. Likewise, it presents a great reduction in volume resulting from the contraction of the gray matter. Consequently, aging can affect not only cognitive functions, including learning and memory, but also the quality of life of older people. As a result of the phenomena, various molecules with notable neuroprotective capacity have been proposed, which provide a therapeutic alternative for people under conditions of aging or some neurodegenerative diseases. It is important to indicate that in recent years the use of molecules with neurotrophic activity has shown interesting results when evaluated in in vivo models. This review aims to describe the neurotrophic potential of molecules such as resveratrol (3,5,4'-trihydroxystilbene), neurotrophins (brain-derived neurotrophic factor), and neurotrophic-type compounds such as the terminal carboxyl domain of the heavy chain of tetanus toxin, cerebrolysin, neuropeptide-12, and rapamycin. Most of these molecules have been evaluated by our research group. Studies suggest that these molecules exert an important therapeutic potential, restoring brain function in aging conditions or models of neurodegenerative diseases. Hence, our interest is in describing the current scientific evidence that supports the therapeutic potential of these molecules with active neurotrophic.

Indexed as

Alzheimer’s diseasebraincerebral cortexcognitive functiondendritic spinesHC-TeTxhippocampusneurodegenerationneuronal survivalneurotrophins

Identifiers

PMID35799508
PMCPMC9241392

What Socratic holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.